Literature DB >> 29030378

Worsening Guillain-Barré syndrome: harbinger of IRIS in HIV?

Neeharika L Mathukumalli1, Niloufer Ali1, Meena A Kanikannan1, Sireesha Yareeda1.   

Abstract

We report an HIV patient aged 38 years with acute inflammatory demyelinating polyradiculoneuropathy subtype of Guillain-Barré syndrome (GBS) as the only manifestation of seroconversion and worsening of GBS being the harbinger of immune reconstitution inflammatory syndrome (IRIS). To date, only 5 cases of GBS during IRIS are reported. They manifested either during the third week or later after starting highly active antiretroviral therapy (HAART). Our patient witnessed worsening weakness by fifth day after starting HAART, even before the occurrence of Pneumocystis jirovecii pneumonia, cautioning one of the impending serious complications of IRIS and helped us initiate steroids at an early date. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29030378      PMCID: PMC5652629          DOI: 10.1136/bcr-2017-221874

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV.

Authors:  P Makela; L Howe; S Glover; I Ferguson; A Pinto; M Gompels
Journal:  J Infect       Date:  2002-01       Impact factor: 6.072

2.  Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children.

Authors:  Thanyawee Puthanakit; Peninnah Oberdorfer; Noppadon Akarathum; Pornphun Wannarit; Thira Sirisanthana; Virat Sirisanthana
Journal:  Pediatr Infect Dis J       Date:  2006-01       Impact factor: 2.129

3.  Guillain--Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection.

Authors:  E C Y Teo; A Azwra; R L Jones; Brian G L Gazzard; Mark Nelson
Journal:  J HIV Ther       Date:  2007-09

Review 4.  Pathogenesis of the immune reconstitution inflammatory syndrome affecting the central nervous system in patients infected with HIV.

Authors:  Guillaume Martin-Blondel; Pierre Delobel; Antoine Blancher; Patrice Massip; Bruno Marchou; Roland S Liblau; Lennart T Mars
Journal:  Brain       Date:  2011-01-18       Impact factor: 13.501

5.  Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus.

Authors:  D A Cooper; B Tindall; E J Wilson; A A Imrie; R Penny
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

6.  Acute neuropathy coincident with seroconversion for anti-LAV/HTLV-III.

Authors:  A M Piette; F Tusseau; D Vignon; A Chapman; G Parrot; J Leibowitch; L Montagnier
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

7.  Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.

Authors:  M A French; N Lenzo; M John; S A Mallal; E J McKinnon; I R James; P Price; J P Flexman; M L Tay-Kearney
Journal:  HIV Med       Date:  2000-03       Impact factor: 3.180

8.  Guillain-Barré syndrome associated with immune reconstitution.

Authors:  Peter J Piliero; Douglas G Fish; Sandra Preston; Donna Cunningham; Tosca Kinchelow; Miklos Salgo; Jiang Qian; George L Drusano
Journal:  Clin Infect Dis       Date:  2003-04-14       Impact factor: 9.079

9.  Guillain Barre syndrome in an HIV-1-infected patient after the beginning of combined antiretroviral therapy: an immune reconstitution inflammatory syndrome?

Authors:  Alessandra Fantauzzi; Maria Anna Digiulio; Eugenio Nelson Cavallari; Gabriella d'Ettorre; Vincenzo Vullo; Ivano Mezzaroma
Journal:  New Microbiol       Date:  2014-01-15       Impact factor: 2.479

  9 in total
  1 in total

Review 1.  Guillain-Barré syndrome spectrum as manifestation of HIV-related immune reconstitution inflammatory syndrome: case report and literature review.

Authors:  José E Vidal; Bruno F Guedes; Hélio R Gomes; Rodrigo Holanda Mendonça
Journal:  Braz J Infect Dis       Date:  2022-05-21       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.